SOURCE: CLX Medical, Inc.

April 23, 2008 09:45 ET

CLX Medical, Inc. Targets Master Distributor for Its Medical Diagnostic Testing Products in the European Market

MURRIETA, CA--(Marketwire - April 23, 2008) - CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today announced that the company has identified and is in negotiations with a major European distributor to serve as the sole importer of CLX's subsidiary products into the European market.

The master distributor will provide product support and product packaging control; coordinate sales to other European distributors; distribute products in its own territory; act as the registered EU representative for CE marked products; and assist with the development and implementation of pricing structures.

"A highly capable and established master distributor for the European market will provide a number of significant advantages for CLX as we pursue widespread distribution for our subsidiary products and additional medical diagnostic tests that we may choose to acquire or license," stated Vera Leonard, chief executive officer of Zonda and CLX. "We are pleased to have identified just such a company, which we believe will serve as a true partner as we seek to expand distribution of our products in the European market.

"We expect to successfully complete negotiations and enter into an agreement with the prospective master distributor. Key terms of the relationship have been agreed upon and we are moving forward with definitive negotiations," added Ms. Leonard.

CLX currently holds a majority interest in Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests, including a rapid point of care test for chlamydia. Zonda's chlamydia product has been distributed in Europe for approximately three years.

CLX is currently preparing to initiate clinical trials for Zonda's HandiLab-C test for Chlamydia as part of the process to achieve FDA clearance for the product. With FDA clearance, CLX will seek to achieve widespread distribution for the HandiLab-C within the U.S., as well as broader distribution into worldwide markets. As part of the preparation for clinical trials, a validation study has been commissioned in order to perfect the testing protocol.

Results from the validation study may be helpful in other applications, such as in overseas markets where additional clinical data can support the sales of the products currently in the market. CLX may also pursue a strategic alliance relationship with an established company in the U.S. medical diagnostic testing market to provide resources and assistance through the clinical trials and FDA clearance application process, and the validation study may help to secure such a relationship.

In addition to Zonda's chlamydia product, CLX recently announced that the company has identified a rapid diagnostic device for the medical market that it has targeted for potential acquisition. As additional due diligence and negotiations are undertaken, the company expects to enter into an initial agreement in the form of a letter of intent for the acquisition of the device.

To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit

About CLX Medical, Inc.

CLX Medical, Inc. ( holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (, a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, Inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications, Inc.
    A. Beyer
    Email Contact